China is reportedly close to adding 300 drugs to the National Reimbursement Drug List, the first update since 2009; Vincent Medical Holdings of Hong Kong invested $3 million into Israel’s Inovytec, a medical device company, for a 15% stake in Inovytec and China rights to its products; SynTheAll Pharma, WuXi AppTec’s small-molecule CRO/CMO, will add staff and capacity to its one-year-old Changzhou campus; French medical device maker Vexim contracted with an unnamed China lab to begin China registration work for its vertebra fracture repair device; and FibroGen, a US-China novel drug company, reported positive results from two China Phase III trials of a treatment for anemia.
